{"schema_version":"secwatch.filing_event.v1","accession":"0001746473-24-000169","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.446580+00:00","generated_at":"2026-05-30T03:40:43.931100+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pliant Therapeutics Q3 net loss $57.8M; BEACON-IPF enrollment on track for Q1 2025","bullets":["Net loss of $57.8M vs $41.5M in Q3 2023; R&D expenses rose to $47.8M on BEACON-IPF trial.","Cash and investments of $406.0M as of Sept 30, 2024; no revenue reported.","BEACON-IPF Phase 2b/3 trial enrolling well; full enrollment expected Q1 2025, data mid-2026.","Phase 1 trial of PLN-101095 in solid tumors dosing third cohort; preliminary data early 2025.","Gary Palmer appointed SVP of Medical Affairs; brings 25+ years from Bristol Myers Squibb."],"urls":{"canonical":"https://secwatch.observer/filing/0001746473-24-000169","json":"https://secwatch.observer/filing/0001746473-24-000169.json","markdown":"https://secwatch.observer/filing/0001746473-24-000169.md","text":"https://secwatch.observer/filing/0001746473-24-000169.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000174647324000169/0001746473-24-000169-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000174647324000169/plrx-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:40:43.931100+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}